Oncol Rep 41: 643-649, 2019; DOI: 10.3892/or.2018.6813
Subsequent to the publication of the above article, the authors have realized that errors were introduced into Fig. 4 at the typesetting stage. Essentially, in Fig. 4B, the P-value should have read as “P=0.13” (not as 0.013), and in Fig 4D, the labels for OBP− and OBP+ were set the wrong way around. The correct version of Fig. 4, as originally submitted, is shown opposite.
Figure 4.
OBP-801 inhibits ARMS tumor growth and improves survival in vivo. (A) Six mice xenografted with luciferase-positive Rh30 cells were treated with vehicle or OBP-801 (10 mg/kg) for 6 weeks, starting on day 3 after tumor injection. We measured tumor-derived bioluminescence starting 3 days after beginning the treatment. Scale bar, 3.0 cm (B and C) Effect of OBP-801 on tumor growth and body weight in nude mice with subcutaneous xenografted RMS tumors (Rh30). Points indicate the mean tumor volumes or body weights (n=4); bars, SD. (D) Kaplan-Meier survival curve of xenografted mice treated with vehicle or OBP-801.
The Editor apologizes to the authors for introducing these errors into their figure, and to the readership for any inconvenience caused.